cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.22619005.v1
title: Additional file 1 of Pathobionts from chemically disrupted gut microbiota induce insulin-dependent diabetes in mice

description: Additional file 1: Fig. S1. Fasting C-Peptide in the mice with and without 0.2% DSS. Fig. S2. Serum amylase (AMS) and serum lipase levels in each group. Fig. S3. 0.2% DSS increased food and water intake but did not change energy intake of mice. Fig. S4. 0.2% DSS did not change the lipid accumulation in mice. Fig. S5. 0.2% DSS did not impair gut barrier integrity and induce inflammation. Fig. S6. qPCR of 16S rRNA gene in fecal samples. Fig. S7. The gut microbiota had been depleted by more than 99% in the mice with a cocktail of antibiotics for 5 weeks. Fig. S8. The recipient mice developed a gut microbiota more similar to their donor mice. Fig. S9. Optimal classification performance of the sPLS-DA model of the gut microbial structure in NC and DSS mice. Fig. S10. Fluorescence in situ hybridization (FISH) of 16S rRNA in the pancreas of antibiotic treated mice. Fig. S11. Fluorescence in situ hybridization (FISH) of 16S rRNA in the pancreas in fecal microbiota transplanted mice. Fig. S12. The bacterial load in the liver as measured by real-time qPCR of 16S rRNA gene. Fig. S13. Flow cytometry evaluation of subtypes of leukocytes in the pancreas of FMNC and FMDSS mice. Fig. S14. 0.2% DSS did not enrich bacteria in pacreas and disrupt the immune tolerance in antibiotic treated mice. Fig. S15. Identification of Muribaculaceae strain MF 13079. Fig. S16. Functional annotation of flagella-related genes and motility test of MF13079. Fig. S17. Bacteria load in mesenteric lymph nodes (MLN) in Akk and Muri mice. Fig. S18. Bray-Curtis Distance based on 16S rRNA sequencing data of gut microbiota between recipient mice and human donors. Fig. S19. Fluorescence in situ hybridization (FISH) of 16S rRNA in the pancreas. Tables S1. Culture medium used for isolation of Muribaculeae. Table S2. COG in the genome of MF 13079.
DOI: 10.6084/m9.figshare.24612237.v1
title: Regulating Protein Corona on Nanovesicles by Glycosylated Polyhydroxy Polymer Modification for Efficient Drug Delivery

description: Source data
DOI: 10.6084/m9.figshare.13708364
title: A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia

description: To evaluate the efficacy and safety of oral sitafloxacin versus oral moxifloxacin in the treatment of Chinese adults with community-acquired pneumonia (CAP). This is a multicenter, randomized, open-label, positive-controlled clinical trial (chinadrugtrials.org.cn identifier: CTR20130046). CAP patients received sitafloxacin tablets 100 mg once daily (qd) or 100 mg twice daily (bid) to compare with moxifloxacin tablets 400 mg qd, for 7–10 days. The primary outcome was non-inferiority of sitafloxacin to moxifloxacin in clinical cure rate at test of cure (TOC) visit in per-protocol set (PPS). A total of 343 patients were randomized (sitafloxacin 100 mg qd, <i>n</i> = 117; sitafloxacin 100 mg bid, <i>n</i> = 116; moxifloxacin, <i>n</i> = 110), 291 patients were included in the PPS (sitafloxacin 100 mg qd, <i>n</i> = 96; sitafloxacin 100 mg bid, <i>n</i> = 94; moxifloxacin, <i>n</i> = 101). The clinical cure rate was 94.8% in the sitafloxacin 100 mg qd group, 96.8% in the sitafloxacin 100 mg bid group and 95.0% in the moxifloxacin group. At the TOC visit, the microbiological success rate was 97.0% (32/33) in the sitafloxacin 100 mg qd group, 97.1% (34/35) in the sitafloxacin 100 mg bid group and 94.9% (37/39) in the moxifloxacin group in the microbiological evaluable set (MES). The incidence of study-drug-related adverse events (AEs) was 23.3% (27/116) in the sitafloxacin 100 mg qd group, 29.8% (34/114) in the sitafloxacin 100 mg bid group and 28.2% (31/110) in the moxifloxacin group (<i>p</i> &gt; .05). The common AEs related to study drug were dizziness, nausea, diarrhea, increased platelet count and alanine transaminase (ALT) elevation. All the AEs resolved completely after discontinuation of study drug. Sitafloxacin 100 mg qd or 100 mg bid for 7–10 days is not inferior to moxifloxacin 400 mg qd for 7–10 days in clinical efficacy for adult CAP patients. Sitafloxacin provides a safety profile comparable to moxifloxacin.
DOI: 10.6084/m9.figshare.24948117
title: Visualization-enhanced Under-oil Open Microfluidic System for in situ Characterization of Multi-phase Chemical Reactions

description: Supporting dataset for Visualization- Enhanced Under-Oil Open Microfluidic System for In Situ Characterization of Multi-Phase Chemical Reactions
DOI: 10.6084/m9.figshare.24612237
title: Regulating Protein Corona on Nanovesicles by Glycosylated Polyhydroxy Polymer Modification for Efficient Drug Delivery

description: Source data
DOI: 10.6084/m9.figshare.13708364.v2
title: A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia

description: To evaluate the efficacy and safety of oral sitafloxacin versus oral moxifloxacin in the treatment of Chinese adults with community-acquired pneumonia (CAP). This is a multicenter, randomized, open-label, positive-controlled clinical trial (chinadrugtrials.org.cn identifier: CTR20130046). CAP patients received sitafloxacin tablets 100 mg once daily (qd) or 100 mg twice daily (bid) to compare with moxifloxacin tablets 400 mg qd, for 7–10 days. The primary outcome was non-inferiority of sitafloxacin to moxifloxacin in clinical cure rate at test of cure (TOC) visit in per-protocol set (PPS). A total of 343 patients were randomized (sitafloxacin 100 mg qd, <i>n</i> = 117; sitafloxacin 100 mg bid, <i>n</i> = 116; moxifloxacin, <i>n</i> = 110), 291 patients were included in the PPS (sitafloxacin 100 mg qd, <i>n</i> = 96; sitafloxacin 100 mg bid, <i>n</i> = 94; moxifloxacin, <i>n</i> = 101). The clinical cure rate was 94.8% in the sitafloxacin 100 mg qd group, 96.8% in the sitafloxacin 100 mg bid group and 95.0% in the moxifloxacin group. At the TOC visit, the microbiological success rate was 97.0% (32/33) in the sitafloxacin 100 mg qd group, 97.1% (34/35) in the sitafloxacin 100 mg bid group and 94.9% (37/39) in the moxifloxacin group in the microbiological evaluable set (MES). The incidence of study-drug-related adverse events (AEs) was 23.3% (27/116) in the sitafloxacin 100 mg qd group, 29.8% (34/114) in the sitafloxacin 100 mg bid group and 28.2% (31/110) in the moxifloxacin group (<i>p</i> &gt; .05). The common AEs related to study drug were dizziness, nausea, diarrhea, increased platelet count and alanine transaminase (ALT) elevation. All the AEs resolved completely after discontinuation of study drug. Sitafloxacin 100 mg qd or 100 mg bid for 7–10 days is not inferior to moxifloxacin 400 mg qd for 7–10 days in clinical efficacy for adult CAP patients. Sitafloxacin provides a safety profile comparable to moxifloxacin.
DOI: 10.6084/m9.figshare.24522928.v1
title: Dual heterogeneous interfaces enhance X-ray excited persistent luminescence for low-dose 3D imaging

description: Data for the Figures in this manuscript.
DOI: 10.6084/m9.figshare.24522928
title: Dual heterogeneous interfaces enhance X-ray excited persistent luminescence for low-dose 3D imaging

description: Data for the Figures in this manuscript.
DOI: 10.6084/m9.figshare.24948117.v1
title: Visualization-enhanced Under-oil Open Microfluidic System for in situ Characterization of Multi-phase Chemical Reactions

description: Supporting dataset for Visualization- Enhanced Under-Oil Open Microfluidic System for In Situ Characterization of Multi-Phase Chemical Reactions
DOI: 10.6084/m9.figshare.13708364.v1
title: A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia

description: To evaluate the efficacy and safety of oral sitafloxacin versus oral moxifloxacin in the treatment of Chinese adults with community-acquired pneumonia (CAP). This is a multicenter, randomized, open-label, positive-controlled clinical trial (chinadrugtrials.org.cn identifier: CTR20130046). CAP patients received sitafloxacin tablets 100mg once daily (qd) or 100mg twice daily (bid) to compare with moxifloxacin tablets 400mg qd, for 7-10 days. The primary outcome was non-inferiority of sitafloxacin to moxifloxacin in clinical cure rate at test of cure (TOC) visit in per-protocol set (PPS). A total of 343 patients were randomized (sitafloxacin 100mg qd, <i>n</i> = 117, sitafloxacin 100mg bid, <i>n</i> = 116, moxifloxacin, <i>n</i> = 110), 291 patients were included in PPS (sitafloxacin 100mg qd, <i>n</i> = 96, sitafloxacin 100mg bid, <i>n</i> = 94, moxifloxacin, <i>n</i> = 101). The clinical cure rate was 94.8% in sitafloxacin 100mg qd group, 96.8% in sitafloxacin 100mg bid group, and 95.0% in moxifloxacin group. At TOC visit, the microbiological success rate was 97.0% (32/33) in sitafloxacin 100mg qd group, 97.1% (34/35) in sitafloxacin 100mg bid group, and 94.9% (37/39) in moxifloxacin group in microbiological evaluable set (MES). The incidence of study drug-related adverse events (AEs) was 23.3% (27/116) in sitafloxacin 100mg qd group, 29.8% (34/114) in sitafloxacin 100mg bid group, and 28.2% (31/110) in moxifloxacin group (<i>P</i> &gt; 0.05). The common AEs related to study drug were dizziness, nausea, diarrhea, increased platelet count, and ALT elevation. All the AEs resolved completely after discontinuation of study drug. Sitafloxacin 100mg qd or 100mg bid for 7-10 days is not inferior to moxifloxacin 400mg qd for 7-10 days in the clinical efficacy for adult CAP patients. Sitafloxacin provides safety profile comparable to moxifloxacin.
DOI: 10.5519/qd.97ea2cu0
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (136 records)
DOI: 10.48425/zz8gw45b
title: V_air_temperature_heath

description: Air temperature measurements in heath sites on the Varanger peninsula.

The dataset includes four different types of files and all data files are saved as ;-separated txt-files (except the readme):

* One data file per year (V_air_temperature_heath_YEAR.txt)
* One meatadata file per year with dates when the loggers were deployed and collected (V_air_temperature_heath_metadata_YEAR.txt)
* One coordinate file with coordinates of all sites (V_air_temperature_heath_coordinates.txt)
* One auxiliary file with information about which sites are included in the study design (V_air_temperature_heath_aux.txt)
* One readme file with additional information (_readme.pdf)
DOI: 10.6084/m9.figshare.22621244.v1
title: Additional file 8 of Allelic phenotype prediction of phenylketonuria based on the machine learning method

description: Additional file 8: Table S2. Tenfold cross-validation on the training data, with a ratio of 8:2 for training and testing, respectively.
DOI: 10.6084/m9.figshare.22621247
title: Additional file 9 of Allelic phenotype prediction of phenylketonuria based on the machine learning method

description: Additional file 9: Table S3. Independent validation by 20% of collection data.
DOI: 10.6084/m9.figshare.22621247.v1
title: Additional file 9 of Allelic phenotype prediction of phenylketonuria based on the machine learning method

description: Additional file 9: Table S3. Independent validation by 20% of collection data.
DOI: 10.6084/m9.figshare.22621205
title: Additional file 2 of Allelic phenotype prediction of phenylketonuria based on the machine learning method

description: Additional file 2: Table S1. Allele mutations associated with PKU phenotypes.
DOI: 10.6084/m9.figshare.22621244
title: Additional file 8 of Allelic phenotype prediction of phenylketonuria based on the machine learning method

description: Additional file 8: Table S2. Tenfold cross-validation on the training data, with a ratio of 8:2 for training and testing, respectively.
DOI: 10.6084/m9.figshare.22621148.v1
title: Additional file 4 of Thermotolerance improvement of engineered Saccharomyces cerevisiae ERG5 Delta ERG4 Delta ERG3 Delta, molecular mechanism, and its application in corn ethanol production

description: Additional file 4. S. cerevisiae DEGs.
DOI: 10.6084/m9.figshare.22621279.v1
title: Additional file 2 of Single-nucleus gene and gene set expression-based similarity network fusion identifies autism molecular subtypes

description: Additional file 2. Table S2: Molecular subtype-specific DEGs unique to subtypes along with the regulation direction and |logFC| relative to other molecular subtypes, and those differentially regulated among different molecular subtypes relative to controls.
DOI: 10.6084/m9.figshare.22621288
title: Additional file 5 of Single-nucleus gene and gene set expression-based similarity network fusion identifies autism molecular subtypes

description: Additional file 5. Table S5: Molecular subtype-specific DEGSs unique to subtypes along with the regulation direction and |logFC| relative to other molecular subtypes, and those differentially regulated among different molecular subtypes relative to controls.
DOI: 10.6084/m9.figshare.22621276
title: Additional file 1 of Single-nucleus gene and gene set expression-based similarity network fusion identifies autism molecular subtypes

description: Additional file 1. Table S1: Molecular subtype-specific DEGs information, the enrichment with SFARI ASD genes, and the association with clinical scores.
DOI: 10.6084/m9.figshare.25182362.v2
title: Data.zip

description: This is the paper data.
DOI: 10.6084/m9.figshare.8989889
title: Additional file 1: of Genetic diversity, linkage disequilibrium, and population structure analysis of the tea plant (Camellia sinensis) from an origin center, Guizhou plateau, using genome-wide SNPs developed by genotyping-by-sequencing

description: Table S1. The quality control (QC) data of each sample. Table S2. Statistics of individual heterozygosity of 287,408 SNPs based on GBS. Table S3.. Statistics of individual heterozygosity of 79,016 SNPs based on GBS. Table S4. SNP density of scaffolds based on GBS. Table S5. The p-value of genetic diversity parameters in Table 2 based on independent-samples T-test. Table S6. Genetic diversity parameters of three species of tea plants in Guizhou Plateau. Table S7. Fst and pairwise genetic distance among three Species of tea plant in Guizhou Plateau (XLSX 117 kb)
DOI: 10.6084/m9.figshare.22621282
title: Additional file 3 of Single-nucleus gene and gene set expression-based similarity network fusion identifies autism molecular subtypes

description: Additional file 3. Table S3: GO and KEGG enrichment analysis of molecular subtype-specific DEGs.
DOI: 10.6084/m9.figshare.22621285.v1
title: Additional file 4 of Single-nucleus gene and gene set expression-based similarity network fusion identifies autism molecular subtypes

description: Additional file 4. Table S4: Molecular subtype-specific DEGSs, the enrichment with SFARI ASD genes, and the association with clinical scores.
DOI: 10.6084/m9.figshare.22621291.v1
title: Additional file 6 of Single-nucleus gene and gene set expression-based similarity network fusion identifies autism molecular subtypes

description: Additional file 6. Table S6: The clinical information of ASD patients in each molecular subtype, and the result of t test between each molecular subtype and the other two for each category of ADI-R scores.
DOI: 10.6084/m9.figshare.22621279
title: Additional file 2 of Single-nucleus gene and gene set expression-based similarity network fusion identifies autism molecular subtypes

description: Additional file 2. Table S2: Molecular subtype-specific DEGs unique to subtypes along with the regulation direction and |logFC| relative to other molecular subtypes, and those differentially regulated among different molecular subtypes relative to controls.
DOI: 10.6084/m9.figshare.22621288.v1
title: Additional file 5 of Single-nucleus gene and gene set expression-based similarity network fusion identifies autism molecular subtypes

description: Additional file 5. Table S5: Molecular subtype-specific DEGSs unique to subtypes along with the regulation direction and |logFC| relative to other molecular subtypes, and those differentially regulated among different molecular subtypes relative to controls.
DOI: 10.6084/m9.figshare.22621205.v1
title: Additional file 2 of Allelic phenotype prediction of phenylketonuria based on the machine learning method

description: Additional file 2: Table S1. Allele mutations associated with PKU phenotypes.
DOI: 10.6084/m9.figshare.22621291
title: Additional file 6 of Single-nucleus gene and gene set expression-based similarity network fusion identifies autism molecular subtypes

description: Additional file 6. Table S6: The clinical information of ASD patients in each molecular subtype, and the result of t test between each molecular subtype and the other two for each category of ADI-R scores.
DOI: 10.6084/m9.figshare.22621282.v1
title: Additional file 3 of Single-nucleus gene and gene set expression-based similarity network fusion identifies autism molecular subtypes

description: Additional file 3. Table S3: GO and KEGG enrichment analysis of molecular subtype-specific DEGs.
DOI: 10.6084/m9.figshare.25183823
title: Plots & Reference data for: Bonelli’s Eagle electrocution risk in Israel can be reduced by 80% by insulating only 4% of the pylonsOrnithological Applications2024

description: RT Journal ArticleA1 Mayrose, AsafA1 Haviv, EliA1 Hatzofe, OhadA1 Troupin, DavidA1 Elroy, MichalA1 Sapir, NirT1 Bonelli’s Eagle electrocution risk in Israel can be reduced by 80% by insulating only 4% of the pylonsJF Ornithological ApplicationsJO Ornithological ApplicationsYR 2024DO 10.1093/ornithapp/duae004OP duae004SN 0010-5422AB The Bonelli’s Eagle (Aquila fasciata) is a critically endangered species in Israel, with electrocution on power lines posing a serious threat to its population. Because retrofitting of electricity pylons to prevent mortality is a slow and costly process, it is important to prioritize the pylons in the network for quick and efficient mitigation of eagle mortality. To determine which pylons need to be retrofitted, we applied a three-stage maximum entropy modeling process for identifying the risk factors posed by different environmental variables. The environmental feature with the highest correlation to electrocution is the distance to reservoirs (i.e., many electrocution events occur near water reservoirs). The reservoirs are foraging hotspots for Bonelli’s Eagles in Israel’s arid environment. Electricity pylons powering the reservoirs’ pumping facilities tend to be the highest perches in the vicinity of many of the reservoirs, creating an ecological trap. The strong attraction of reservoirs to eagles may explain the high level of selectivity indicated by the model, suggesting that retrofitting only 3.6% of the pylons in the network would achieve 77% reduction in eagles’ electrocution probability. Moreover, insulating pylons according to the model will also likely reduce electrocutions of other avian species, including Eastern Imperial Eagle (Aquila heliaca) and White-tailed Eagle (Haliaeetus albicilla). The modeling process presented here yielded two electrocution risk maps, one to facilitate prioritization of mitigation in Israel’s existing power network and the second to support planning and designing new infrastructure. The model may help reach conservation goals for Bonelli’s Eagle and may also be useful in prioritizing pylon retrofitting in other arid landscapes.RD 2/8/2024UL https://doi.org/10.1093/ornithapp/duae004
DOI: 10.6084/m9.figshare.8989892
title: Additional file 2: of Genetic diversity, linkage disequilibrium, and population structure analysis of the tea plant (Camellia sinensis) from an origin center, Guizhou plateau, using genome-wide SNPs developed by genotyping-by-sequencing

description: Information of 415 tea accessions used in this study, including the accession/clone/collection, the accession name, the zone, the cultivation status, growth habits, the species, the STRUCTURE URE-based grouping (Qi â Ľ0.8) at Kâ =â 2, the notes, the source, and the inferred populations (XLSX 45 kb)
DOI: 10.6084/m9.figshare.8989889.v1
title: Additional file 1: of Genetic diversity, linkage disequilibrium, and population structure analysis of the tea plant (Camellia sinensis) from an origin center, Guizhou plateau, using genome-wide SNPs developed by genotyping-by-sequencing

description: Table S1. The quality control (QC) data of each sample. Table S2. Statistics of individual heterozygosity of 287,408 SNPs based on GBS. Table S3.. Statistics of individual heterozygosity of 79,016 SNPs based on GBS. Table S4. SNP density of scaffolds based on GBS. Table S5. The p-value of genetic diversity parameters in Table 2 based on independent-samples T-test. Table S6. Genetic diversity parameters of three species of tea plants in Guizhou Plateau. Table S7. Fst and pairwise genetic distance among three Species of tea plant in Guizhou Plateau (XLSX 117 kb)
DOI: 10.6084/m9.figshare.8989892.v1
title: Additional file 2: of Genetic diversity, linkage disequilibrium, and population structure analysis of the tea plant (Camellia sinensis) from an origin center, Guizhou plateau, using genome-wide SNPs developed by genotyping-by-sequencing

description: Information of 415 tea accessions used in this study, including the accession/clone/collection, the accession name, the zone, the cultivation status, growth habits, the species, the STRUCTURE URE-based grouping (Qi â Ľ0.8) at Kâ =â 2, the notes, the source, and the inferred populations (XLSX 45 kb)
DOI: 10.6084/m9.figshare.22621162
title: Additional file 1 of Multiple founding paternal lineages inferred from the newly-developed 639-plex Y-SNP panel suggested the complex admixture and migration history of Chinese people

description: Additional file 1: Table S1 Haplogroup distribution of all studied populations. Table S2 Haplogroup frequency of 33 Chinese populations. Table S3 Genetic distances among 33 Chinese populations. Table S4 Haplogroups of 4727 people from 114 populations.
DOI: 10.6084/m9.figshare.22621276.v1
title: Additional file 1 of Single-nucleus gene and gene set expression-based similarity network fusion identifies autism molecular subtypes

description: Additional file 1. Table S1: Molecular subtype-specific DEGs information, the enrichment with SFARI ASD genes, and the association with clinical scores.
DOI: 10.6084/m9.figshare.22621285
title: Additional file 4 of Single-nucleus gene and gene set expression-based similarity network fusion identifies autism molecular subtypes

description: Additional file 4. Table S4: Molecular subtype-specific DEGSs, the enrichment with SFARI ASD genes, and the association with clinical scores.
DOI: 10.6084/m9.figshare.24968556.v1
title: High-Performance Cryo-Temperature Ionic Thermoelectric Liquid Cell Developed through a Eutectic Solvent Strategy

description: This file contain the relevant date generated in the article" High-Performance Cryo-Temperature Ionic Thermoelectric Liquid Cell Developed through a Eutectic Solvent Strategy".
DOI: 10.6084/m9.figshare.24968556
title: High-Performance Cryo-Temperature Ionic Thermoelectric Liquid Cell Developed through a Eutectic Solvent Strategy

description: This file contain the relevant date generated in the article" High-Performance Cryo-Temperature Ionic Thermoelectric Liquid Cell Developed through a Eutectic Solvent Strategy".
DOI: 10.6084/m9.figshare.12135411.v1
title: Additional file 7 of Coordinated mechanisms of leaves and roots in response to drought stress underlying full-length transcriptome profiling in Vicia sativa L

description: Additional file 7 Table S7. Primers used for yeast assays in this study.